Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Indaptus Therapeutics ( (INDP) ).
Indaptus Therapeutics, Inc. announced that it has regained compliance with the Nasdaq’s minimum bid price requirement as of July 14, 2025. This compliance was achieved after the company’s stock maintained a closing bid price of $1.00 or greater for 10 consecutive business days, resolving the previous deficiency issue.
The most recent analyst rating on (INDP) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.
Spark’s Take on INDP Stock
According to Spark, TipRanks’ AI Analyst, INDP is a Underperform.
Indaptus Therapeutics is facing considerable financial and operational difficulties, as highlighted by its poor financial performance with no revenue and continuous losses. The technical analysis further supports a negative outlook, with indicators pointing to bearish momentum. The company’s valuation is unattractive due to its unprofitability and lack of dividends. Collectively, these factors suggest a high-risk investment with limited short-term upside potential.
To see Spark’s full report on INDP stock, click here.
More about Indaptus Therapeutics
Indaptus Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for the treatment of various diseases.
Average Trading Volume: 245,240
Technical Sentiment Signal: Sell
Current Market Cap: $7.2M
For an in-depth examination of INDP stock, go to TipRanks’ Overview page.